Patient Blood Management Market Report 2025

This Patient Blood Management market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The patient blood management market size has grown strongly in recent years. It will grow from $14.86 billion in 2024 to $15.94 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, increasing number of surgical procedures, government initiatives, increasing demand for bloodless surgery, rising availability of blood substitutes, rising demand for quality healthcare.

The patient blood management market size is expected to see strong growth in the next few years. It will grow to $20.92 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to aging population, growing demand for blood, changing demographics, increasing focus on personalized medicine, growing demand for safe and effective blood transfusions, and increasing healthcare spending. Major trends in the forecast period include patient-centered care, data-driven decision-making, hemoglobin optimization, collaborative care, and expanded use of autologous blood.

The increasing incidence of accidents, trauma cases, and surgical procedures has fueled the growth of the global patient blood management market. For example, in September 2023, the UK Department for Transport, a government agency in the UK, reported that the final estimates for road collisions in Great Britain in 2022 showed 1,711 fatalities, with 76% of these fatalities being male and accounting for 62% of all casualties of varying severity. The rise in accidents, trauma cases, and surgical procedures has led to a higher demand for blood and its products, thereby driving the market forward.

The rising number of surgical procedures is anticipated to drive the growth of the patient blood management market in the future. Surgical procedures involve medical interventions that physically manipulate tissues or organs to diagnose, treat, or prevent health conditions, typically requiring incisions and the use of surgical instruments. This increase is attributed to the growing prevalence of chronic diseases, advancements in medical technology, enhanced surgical techniques, and an aging population. Patient blood management improves surgical outcomes by optimizing blood usage, reducing the need for transfusions, minimizing complications, and enhancing results through effective preoperative assessment and anemia management. For instance, in August 2023, The Aesthetic Society, a US-based organization focused on plastic surgery and cosmetic medicine, reported that Americans spent over $11.8 billion on aesthetic procedures, marking a 2% increase from the previous year. Therefore, the rising number of surgical procedures is expected to propel the growth of the patient blood management market.

HEMAsavR, a sterile medical device, is increasingly adopted for capturing and transferring blood in surgical settings to respond swiftly to unforeseen blood loss. This device allows clinicians to collect anticoagulated blood economically without specialized resources, reducing upfront collection costs and potentially avoiding allogenic transfusions. Its use correlates with improved patient outcomes including reduced mortality rates, lower infection incidents, and decreased risk of multi-organ failure.

Major companies in the patient blood management market are concentrating on innovative products, such as medical devices for blood transfusions, to enhance their revenue streams. These medical devices are designed to safely and efficiently transfer blood or blood products from donors to recipients. For example, in May 2024, Becton, Dickinson and Company, a US-based medical technology firm, launched UltraTouch, a device engineered to streamline the blood sample collection process while minimizing patient discomfort. It employs advanced technology to facilitate quick and efficient venipuncture, ensuring high accuracy in sample collection. With a user-friendly interface and ergonomic design, UltraTouch is suitable for healthcare professionals in various settings, including hospitals, clinics, and laboratories. This device is particularly beneficial for patients who feel anxious during blood draws, as its innovative design aims to reduce pain and enhance the overall experience. Additionally, it features safety mechanisms to minimize the risk of needle-stick injuries, making it a preferred choice in modern medical practice.

Major companies operating in the patient blood management market include Haemonetics Corporation, Fresenius SE & Co. KGaA, Terumo Corporation, Immucor Inc., B. Braun Melsungen AG, Macopharma, bioMérieux SA, Asahi Kasei Corporation, KANEKA CORPORATION, Bio-Rad Laboratories Inc, Abbott Laboratories, Grifols, Roche, LIVANOVA PLC, Danaher, Mediware information systems, Kawasumi Laboratories, Haier Biomedical, Diatron MI Zrt., BAG Diagnostics GmbH, Hitachi Ltd., Ortho Clinical Diagnostics, Beckman Coulter Inc., Siemens Healthineers, Thermo Fisher Scientific Inc., Sysmex Corporation, Nihon Kohden Corporation, Radiometer Medical ApS, Instrumentation Laboratory, F. Hoffmann-La Roche Ltd, Grifols Diagnostic Solutions Inc., HemoCue AB.

Patient blood management is a patient-centric and evidence-based strategy designed to optimize patient care, particularly for those potentially requiring blood transfusions. It aims to enhance patients' own blood, minimize blood loss during surgeries, and utilize the body's natural reserves to manage anemia, ultimately reducing the reliance on external blood transfusions.

Within patient blood management, products are categorized into instruments, accessories, reagents, kits, and software. These kits play a role in managing a patient's blood. Additionally, patient blood management is categorized by blood components such as plasma, whole blood, and red blood cells, utilized across various healthcare settings including hospitals, clinics, and other medical facilities.

The patient blood management market research report is one of a series of new reports that provides patient blood management market statistics, including patient blood management industry global market size, regional shares, competitors with a patient blood management market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the patient blood management industry. This patient blood management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the patient blood management market in 2024. Western Europe was the second-largest region in the patient blood management market share. The regions covered in the patient blood management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the patient blood management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The patient blood management market includes revenues earned by instruments, blood processing devices, and centrifuges. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.